YaSheng Group's Biotech Science Research Center Patents Human DNA
Technology That Is an Alternative to Antibiotics

The YaSheng Group (OTC: YHGG) achieved a breakthrough in Lysozyme
DNA Technology as reported by the company's Academy of Science
Research and Development Center. YaSheng was awarded the patent for
this newly developed technology under authorized patent
(ZL03100582.9) and International patent (C12N15/62). If sold for
$50/gram, YaSheng Group believes they can obtain annual sales of US
$525,000,000 from this Patent.

Scientists at YaSheng Group reported that the Lysozyme they
developed can eliminate Bacteria effectively without harmful side-
effects; a great alternative to existing antibiotics which limits
bacterial-growth. Lysozyme contains functions that strengthen the
immune system, reduce inflammation and cell growth with demonstrated
results in the prevention of oral cavity and respiratory tract.

The company reported a number of uses in this Lysozyme technology.
Lysozyme can be used as an antiseptic for the food industry and
serve as an essential additive to promote child growth. It can be
utilized in baby food, powered formula and drinks. Adding Lysozyme
to milk will make its characteristics closer to human milk.
Furthermore, Lysozyme can also be utilized in dairy farming as a
form of medication to prevent cow Mastitis. In the past, a common
practice to handle cow Mastitis was through elimination and
slaughter of herds, resulting in tremendous economic loss. Lysozyme
had proven to be an effective treatment to eliminate cow mastitis.

The YaSheng Group Academy of Sciences Research and Development
Center is in the process of applying Lysozyme DNA technology against
Acquired Immune Deficiency Syndrome (AIDS HIV). This research had
received strong support by the Chinese Government to further address
the rising issue in China. Clinical medication for AIDS is typically
expensive and is limited to only controlling the condition while
contributing serious side effects. The scientific research team of
YaSheng hopes to develop a new alternative for the treatment of
(AIDS HIV-1) by creating cell activities which causes a high
resistance to AIDS.

The market potential for Lysozyme is tremendous because of its
flexibility, multiple applications and numerous benefits. It is not
currently produced on an industrial level and is regarded highly by
the bio-medical community. YaSheng plans to further enhance the
development of Lysozyme and plans to utilize this new technology
across a number of the company's subsidiaries. The company's
pharmaceutical division had produced transgenic Lysozyme plants as
an herbal and food product with strong properties in health. In
addition, YaSheng will apply the new technology to agricultural
fields for improvement of crop varieties and increase ability to
resist bacteria in plants.

Additional uses for this patent can be viewed at:

www.yashenggroup.com/news_human_lysozyme.htm

About YaSheng Group:

The YaSheng Group (OTC: YHGG), a diversified industrial conglomerate
incorporated in Redwood City, California, operates in hi-tech
agriculture, salt chemistry and biological technology as its core
business with advantages in land, mineral resources, capital and
technology reserves.

Through its 136 subsidiaries, the company operating categories
include: chemical engineering, agricultural production, biotech,
pharmaceuticals, textile products, commercial trading, beverages and
inorganic salt manufacturing. With total assets of approximately
$1.5 billion USD and over 15,000 employees, YaSheng Group has
155,097,355 shares issued and outstanding as of December 1, 2004.

Further information concerning YaSheng Group can be found on the
corporate website: www.yashenggroup.com

Forward-Looking Statements:

Certain statements contained in this press release are forward-
looking statements that involve risks and uncertainties. The
statements contained herein that are not purely historical are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended.

Arizona Biotech

Biotech News

Arizona Entrepreneurs

Arizona High Tech